Business
Genflow to Attend Healthcare Conference
Genflow Biosciences Plc announced its attendance at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, aiming to engage with potential partners and investors regarding its longevity gene-therapy pipeline, specifically its SIRT6 longevity pathway focus and lipid nanoparticle delivery for mRNA SIRT6 therapeutics. The company's CEO highlighted the opportunity for strategic partnerships in the longevity space. Disclaimer*
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\n \n \nGenflow Biosciences Plc\n \nGenflow to Attend the 44th Annual J.P. Morgan Healthcare Conference\n \n \nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12-15, 2026, at the Westin St. Francis in San Francisco, California.\n \nJ.P. Morgan's Healthcare Conference is the sector's most influential global investment gathering, connecting industry leaders, high-growth innovators, and the investment community. Genflow's participation provides an opportunity to engage with potential partners, institutional investors, and pharmaceutical companies as the Company advances its gene-therapy pipeline targeting the SIRT6 longevity pathway.\n \nAbout the 44th Annual J.P. Morgan Healthcare Conference\nThe 44th Annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together global industry leaders, emerging growth companies, technology innovators, and investors. More information is available on the conference website.\n \nDr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"\n \nContacts\n\n\n\n\nGenflow Biosciences\n\n\nHarbor Access \n\n\n\n\nDr Eric Leire, CEO\n\n\nJonathan Paterson, Investor Relations\n\n\n\n\n+32-477-495-881\n\n\n+1 475 477 9401\n\n\n\n\n\n\n\[email protected]\n\n\n\n\n \nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing agi...